Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: A phase 1/2 trial
    Meeting Abstract

    Nassiri, F.; Patil, V.; Yefet, L.; Singh, O.; Liu, J.; Dang, R.; Yamaguchi, T.; Daras, M.; Cloughesy, T.; Colman, H.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • CNSONTRK study: Clinical characteristics and outcome of central nervous system tumors harboring NTRK gene fusions
    Meeting Abstract

    Lamoureux, A. A.; Fisher, M.; Lemelle, L.; Pfaff, E.; De Wilde, B.; Pfister, S.; Sturm, D.; Orbach, D.; Raskin, S.; Drilon, A.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Application of the GBM-X data platform to estimate treatment effects of the experimental therapies of the randomized phase 2 individualized screening trial of innovative glioblastoma therapies
    Meeting Abstract

    Rahman, R.; Trippa, L.; Fell, G.; Lee, E.; Arrillaga-Romany, I.; Touat, M.; Drappatz, J.; Welch, M.; Galanis, E.; Ahluwalia, M.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Impact of vorasidenib treatment on mutant IDH1 or IDH2 diffuse glioma tumor growth rate: Results from the randomized, double-blind, phase 3 INDIGO study
    Meeting Abstract

    Wen, P.; Mellinghoff, I.; van den Bent, M.; Blumenthal, D.; Touat, M.; Peters, K.; Clarke, J.; Mendez, J.; Yust-Katz, S.; Mason, W.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • A randomized, double-blind phase 3 study of vorasidenib vs placebo in patients with mutant IDH1/2 diffuse glioma (INDIGO): Analysis of health-related quality of life, neurocognition and seizures
    Meeting Abstract

    Peters, K.; Mellinghoff, I.; van den Bent, M.; Blumenthal, D.; Touat, M.; Clarke, J.; Mendez, J.; Yust-Katz, S.; Mason, W.; Ducray, F.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • A randomized double-blind phase 3 study of vorasidenib vs placebo in patients with mutant IDH1/2 diffuse glioma (INDIGO): Exploratory analysis of variant allele frequency and progression-free survival
    Meeting Abstract

    Cloughesy, T.; Mellinghoff, I.; van den Bent, M.; Blumenthal, D.; Touat, M.; Peters, K.; Clarke, J.; Mendez, J.; Yust-Katz, S.; Mason, W.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
    Meeting Abstract

    Venneti, S.; Kawakibi, A. R.; Ji, S.; Waszak, S.; Sweha, S.; Mota, M.; Pun, M.; Deogharkar, A.; Chung, C.; Tarapore, R.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors: An updated analysis
    Meeting Abstract

    Perreault, S.; Doz, F.; Geoerger, B.; Italiano, A.; Lassen, U.; Nilsson, A.; Nysom, K.; Spano, J. P.; Norenberg, R.; Bernard-Gauthier, V.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1/2 study of the WEE1 inhibitor Debio 0123 in combination with temozolomide plus radiotherapy in adults with recurrent or newly diagnosed glioblastoma
    Meeting Abstract

    Roth, P.; Papadopoulos, K. P.; Vieito, M.; Yang, J.; Majd, N.; Sepúlveda, J.; Schaff, L.; Moreno, V.; Pérez-Larraya, J. G.; Micallef, S.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • A randomized, multicenter, double blind, phase 2B study of Igv-001, an autologous cell immunotherapy with antisense oligo IMV-001 targeting IGF-1R, vs placebo, in newly diagnosed glioblastoma patients
    Meeting Abstract

    Lee, I.; Judy, K.; Schulder, M.; Hanft, S.; Evans, L.; Wu, J.; Aulakh, S.; Wong, E.; Agarwal, V.; Ramakrishna, R.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save